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ABSTRACT
A heterogeneous group of cancers for which the site of origin remains occult 
after detailed investigations is defined as carcinomas of unknown primary origin 
(CUPs). Because patients with CUP have a dismal prognosis, we have analyzed 
CUPs to highlight the implication of clinicopathologic factors related with patient 
survival. A total of 106 consecutive cases of CUP were collected. A two-step strategy 
of immunohistochemistry to assess CUPs according NCCN Guidelines is used to 
separate carcinomatous tumors and subtype carcinomas. Median follow up of 
censored patients was 26 months. Median survival time of whole patients was 13 
months (95% confidence interval [CI], 8.43 - 19.1 months), with one, two and five-
year survival rate of 53.7%, 35.1%, and 30.5%, respectively. Factors related with 
shorter overall survival was adenocarcinoma histology (P=0.001), increased CA19-
9 (P=0.003), increased CEA (P=0.047), increased LDH (P<0.001), CK20 positivity 
(P=0.002), presence of bone metastasis (P=0.017), metastasis not confined to 
the lymph nodes (P=0.015), unfavorable clinical group based predefined category 
(P=0.017), and patients with no treatment (P<0.001). Multivariable analysis with 
cox regression model revealed factors related with overall survival; cases belonged to 
Culine’s poor risk group (HR, 3.88; 95% CI, 1.75-8.64; P=0.001) and CK20 positivity 
(HR, 3.31; 95% CI, 1.42-7.70; P=0.005). In conclusion, the CK20 expression profile 
is a prognostic factor in patients with CUP and initial stratification of patient with 
Culine’s model may provide a prognostic information in these patients. Assessment 
of clinical implication of these factors in the context of site specific therapy needs to 
be evaluated.
INTRODUCTION
Carcinoma of unknown primary origin (CUP), 
also known as occult primary tumor is defined as 
histologically proven metastatic malignant tumors whose 
primary site cannot be identified by clinical manifestation, 
radiographic and pathologic examinations [1, 2]. It 
comprises heterogeneous groups of tumor, clinically and 
histologically and about 3% to 5% of all newly diagnosed 
malignant tumors are classified as CUP [2]. 
Among CUPs, adenocarcinoma comprises the 
most common histologic type in reported studies [3, 4]. 
Generally, patients of CUP have poor clinical prognosis 
with limited life expectancy. Median survival of 3 
months in extranodal adenocarcinoma and 8 months in 
metastatic adenocarcinoma limited to lymph node are 
expected in population based analysis [4]. In addition, it 
is rapidly invasive with early dissemination, and shows 
unpredictable pattern of metastatic spread. 
Although the primary site of a CUP remains 
unknown in 20-50% of patient even after a full diagnostic 
workup [5], it is known that a subset of patients with 
CUP shows favorable clinical behavior. Identification of 
this group seems pivotal in the management of patients. 
Favorable subsets of patients accounts for about 20% 
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of those with CUPs, and include women with papillary 
adenocarcinoma of the peritoneal cavity, women with 
adenocarcinoma involving the axillary lymph nodes, 
poorly differentiated carcinoma with midline distribution, 
poorly differentiated neuroendocrine carcinoma, 
squamous cell carcinoma involving cervical lymph 
nodes, adenocarcinoma with a colon-cancer profile, men 
with osteoblastic bone metastases and elevated prostate-
specific antigen, isolated inguinal lymphadenopathy with 
squamous histology, and patients with one, small, or 
potentially resectable tumor [6]. 
The best approach of stepwise algorithm with 
immunohistochemistry (IHC) of biopsied tissue was 
suggested to provide a specific therapy against the most 
likely primary site. Although a number of recent studies 
discussed the use of gene expression-based tests and 
methylation profile in the setting of CUP, practical value 
of this approach in the daily clinical practice is still limited 
[7-10]. Thus, a cost-effective and systemized IHC with 
identification of clinicopathologic factors related with the 
patient prognosis are clinically relevant [11, 12]. Most 
of previous reported publication focused on the usage 
of appropriate IHC panel for the differential diagnosis. 
Limited number of publication described general clinical 
behavior and clinicopathologic factors related with 
them [13, 14]. In the present study, consecutive cases of 
CUPs from one institute were analyzed to highlight the 
implication of clinicopatholoic factors related with patient 
survival.
RESULTS
Patient demographic characteristics and clinical 
manifestation
A total of 106 cases from 106 patients were 
collected from the year of 2000 to 2015. Clinicopathologic 
characteristics of the patients are presented in Table 1. 
Median age at time of diagnosis is 59 (range: 25-83) 
and the number of male patients are sixty nine (65.1%). 
Most common histologic type was adenocarcinoma (43 
cases, 40.6%), followed by squamous cell carcinoma 
(28 cases, 26.4%), poorly differentiated carcinoma (26 
cases, 24.5%) and undifferentiated carcinoma (9 cases, 
8.5%). Representative images of H-E stained section 
are displayed in Figure 1. Cases of poorly differentiated 
carcinoma showing neuroendocrine differentiation, 
confirmed by the IHC, were reported in 4 cases. 
About 72.6% (77 out of 106) of patients were 
treated by chemotherapy and radiation concurrently 
or sequentially. Metastasis to liver, lung, bone and 
brain was noted in 10 (9.4%), 17 (16.0%), 28 (26.4%) 
Figure 1: Representative histological features of cancers of unknown primary origin. Case1; Poorly differentiated carcinoma, 
positive for CK7 and CK20 and focal positive for CDX-2. Case2; Squamous cell carcinoma, positive for CK7. Case3; Undifferentiated 
carcinoma, positive for CK7 and CDX-2 and negative for CK20. 
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Table 1: Clinicopathologic characteristics of patients with CUP
Variable Patients N(%)(total=106) Variable Patients N(%)(total=106)
Age(years) Bone Metastasis
Median 59(25-83) Absent 78(73.6)
<50 28(26.4) Present 28(26.4)
>50 78(73.6) Treatment 
No treatment 19(17.9)
Gender Operation 40(37.7)
Female 37(34.9) Chemotherapy 41(38.7)
Male 69(65.1) Radiation therapy 44(41.5)
Performance Status(ECOG) Concurrent chemo-radiation 16(15.1)
0 13(12.6)
1 86(81.1) CEA
2 4(3.8) Normal 48(45.3)
3 1(0.9) High 32(30.2)
4 2(1.9) Not assessed 26((24.5)
Histology CA19-9
Poorly differentiated carcinoma 26(24.5) Normal 45(42.5)
Adenocarcinoma 43(40.6) High 26(24.5)
Squamous cell carcinoma 28(26.4) Not assessed 35(33.0)
Undifferentiated carcinoma 9(8.5) CA125
Lactate dehydrogenase(IU/L) Normal 16(15.1)
Normal 14(13.2) High 24((22.6)
High 36(34.0) Not assessed 66.(62.3)
Not assessed 56(52.8) CA15-3
CK7 immunosttinng Normal 20(18.9)
Negative 27(25.5) High 6(5.6)
Positive 60(56.6) Not assessed 80(75.5)
Not assessed 19(17.9) AFP
CK20 Immunostaining Normal 48(45.3)
Negative 77(72.6) High 3(2.8)
Positive 10(9.4) Not assessed 55(51.9)
Not assessed 19(17.9) PIVKA-II
CDX2 Immunostaining Normal 18(17.0)
Negative 76(71.7) Increased 12(11.3)
Positive 11(10.4) Not assessed 76(71.7)
Not assessed 19(17.9) SCCAg  
Lung Metastasis Normal 20(18.9)
Absent 89(84.0) Increased 8(7.5)
Present 17(16.0) Not assessed 78(73.6)
Liver Metastasis
Absent 96(90.6) Prognostic group
Present 10(9.4) Favorable 31(29.2)
Brain Metastasis Non-favorable 75(70.8)
Absent 70(66.0) Lower GI profile 
Present 8(7.5) Lower GI profile 6(5.7)
Symptomatically suspicous 2(1.9) Non-Lower GI profile 81(76.4)
Not evaluated 26(24.5) Not assessed 19(17.9)
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and 10 (9.4%) patients, respectively. Tumor markers 
at the time of diagnosis were assessed and elevated 
carcinoembryonic antigen (CEA), cancer antigen (CA) 
19-9, CA125, CA15-3, and alpha fetoprotein (AFP) 
were recorded in 32 (30.2%), 26 (24.5%), 24 (22.6%), 
6 (5.6%) and 3 (2.8%) patients, respectively. When 
CUP patients were categorized into the ‘favorable’ and 
‘non-favorable’ groups based on predefined criteria, 
the number of cases belonging to the favorable group 
was 31 (29.2%), compatible with the previously known 
range of about 80%. Among these 19 patients (17.9%) 
presented as squamous cell carcinoma of the cervical 
lymph nodes, 4 patients presented as poorly differentiated 
carcinoma with neuroendocrine characteristics proven by 
immunohistochemistry, 6 patients with adenocarcinoma 
with colon-cancer profile and 2 male patients with blastic 
bone metastases and elevated prostate-specific antigen. 
Univariate analysis of clinicopathologic factors 
related to the patient’s survival
The overall survival probability for the entire CUP 
study patients is displayed in Figure 2. A total of 39 cases 
were censored and death event were 67 cases. Median 
follow up of censored patients was 26.7 months. Median 
survival time was 13 months (95% confidence interval 
[CI], 8.43 - 19.1 months), with one, two and five-year 
survival rate of 53.7%, 35.1%, and 30.5%,, respectively, 
which is better than reported (Figure 2). 
Given the importance of the identification of 
subgroups with favorable clinical behavior, several 
clinicopathologic factors were analyzed to identify factors 
related with overall survival and are summarized in 
Table 2, Figure 3 and Supplementary Figure 1. Factors 
related with shorter overall survival was presence of bone 
metastasis (P = 0.017), metastasis not confined to the 
lymph nodes (P = 0.002), patients with no treatment (P < 
0.001), adenocarcinoma phenotype (P < 0.001), increased 
CA19-9 (P = 0.003), increased CEA (P = 0.047), patients 
belonging to poor risk group in Culine’s model (P < 0.001) 
and increased lactate dehydrogenase (LDH, P < 0.001). 
In the female subset, patients with axillary lymph node 
metastasis showed tendency of better overall survival, 
although not statistical significant (P = 0.057).
We assessed immunohistochemical results of CK20, 
CK7 and CDX-2 using TMA and analyzed expression 
profiles related with patients’ overall survival. In lower 
gastrointestinal profiles, patients with CK20 positive CUP 
had a poorer overall survival than patients with CK20 
negative CUP (P = 0.002) and CDX-2 expression (P = 
0.042). Patients with CK7 positive CUP also tended to 
have a shorter overall survival than patients with CK7 
negative CUP (P = 0.111). 
Patients belonging to favorable prognostic group 
showed better overall survival than unfavorable group 
with limited statistical significance (P = 0.191). In 
validation of Culine’s prognostic model, median survival 
of good risk patient was 19 months whereas that of poor 
risk patients were 7 months (hazard ratio [HR], 2.45; 95% 
CI, 1.46 - 4.10; P < 0.001). 
Figure 2: A Kaplan-Meier graph of overall survival of all patients.
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Table 2: Univariate analysis of clinicopathologic characteristic related with overall survival 
Variable Patients N(%) Event Median survival(months) P value
Age(years)     
<50 28(26.4) 17 19
0.2238
>50 78(73.6) 50 12
Gender     
Female 37(34.9) 24 12
0.8384
Male 69(65.1) 43 13
Performance Status(ECOG)    
0 13(12.3) 6 78
0.0014
1 86(81.1) 57 12
2 4(3.8) 2 2
3 1(0.9) 0 0
4 2(1.9) 2 1
Histology     
Poorly differentiated carcinoma 26(24.5) 15 18
0.0016
Adenocarcinoma 43(40.6) 32 4
Squamous cell carcinoma 28(26.4) 15 24
Undifferentiated carcinoma 9(8.5) 5 119
Lactate dehydrogenase(IU/L)     
Normal 14(13.2) 4 6
0.0002High 36(34.0) 27 0
Not assessed 56(52.8)   
CK7 immunosttinng     
Negative 27(25.5) 17 24
0.1111
Positive 60(56.6) 42 9
Not assessed 19(17.9)    
CK20 Immunostaining     
Negative 77(72.6) 50 14
0.002
Positive 10(9.4) 9 1
Not assessed 19(17.9)    
CDX2 Immunostaining     
Negative 76(71.7) 51 14
0.0418
Positive 11(10.4) 8 1
Not assessed 19(17.9)    
Lung Metastasis     
Absent 89(84.0) 55 2
0.2142
Present 17(16.0) 12 0
Liver Metastasis     
Absent 96(90.6) 60 13
0.4388
Present 10(9.4) 7 7
Bone Metastasis     
Absent 78(73.6) 47 15
0.0171
Present 28(26.4) 20 5
Brain Metastasis    
Absent 70(66.0) 38 16
0.6027
Present 8(7.5) 8 24
Symptomatically suspicous 2(1.9)    
Not evaluated 26(24.5)    
Treatment     
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Multivariable analysis of clinicopathologic factors 
related to the patient’s survival
For adjustment of parameters affecting a patient’s 
survival, multivariable analysis was performed using Cox 
regression test (Table 3). Multivariable analysis using 
No treatment 19(17.9) 10 2
0.0000
Operation 40(37.7) 11 6
Chemotherapy 41(38.7) 13 13
Radiation therapy 44(41.5) 15 7
Concurrent chemoradiation 16(15.1) 18 34
CEA     
Normal 48(45.3) 30 14
0.0468
High 32(30.2) 23 4
Not assessed 26(24.5)  0  
CA19-9     
Normal 45(42.5) 25 15
0.0031
High 26(24.5) 21 2
Not assessed 35(33.0)  0  
CA125     
Normal 16(15.1) 13 12
0.7652
High 24(22.6) 18 4
Not assessed 66(62.3)  0  
CA15-3     
Normal 20(18.9) 13 13
0.5559
High 6(5.6) 5 4
Not assessed 80(75.5)  0  
AFP   0  
Normal 48(45.3) 31 14
0.1506
High 3(2.8) 2 0
Not assessed 55(51.9)  0  
PIVKA-II    
Normal 18(17.0) 14 6
0.6332
Increased 12(11.3) 9 3
Not assessed 76(71.7)    
SCCAg     
Normal 20(18.9) 14 14 0.6109
Increased 8(7.5) 6 9  
Not assessed 78(73.6)    
Prognostic group   0  
Favorable 31(29.2) 19 20
0.191
Non-favorable 75(70.8) 48 11
Prognostic group (by Culine)     
Good risk 64(60.4) 36 19
0.0005
Poor risk 42(39.6) 31 7
Metastasis confined to lymph node     
Yes 36(34.0) 16 9
0.0015
No 70(66.0) 51 78
Lower GI profile     
Lower GI profile 6(5.7) 5 13
0.126
Non-Lower GI profile 81(76.4) 54 1
Not assessed 19(17.9)    
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adenocarcinoma histology, CK20 positivity, CA19-9 
elevation, metastasis confined to lymph nodes, presence of 
bone metastasis and favorable group defined by Culine’s 
prognostic model was developed. Finally, factors related 
with overall survival were cases belonged to Culine’s poor 
risk group (HR, 3.88; 95% CI, 1.75-8.64; P = 0.001) and 
CK20 positivity (HR, 3.31; 95% CI, 1.42-7.70; P = 0.005). 
DISCUSSION
The clinical presentation of CUP that showed 
early and usually aggressive metastatic dissemination 
with limited life expectancy require the identification 
of favorable patient groups. In the present study, a 
consecutive series of cases of CUPs in one institute 
was analyzed to identify the clinicopathologic factors 
related to patient survival. Limited information was 
provided by previous literature regarding the natural 
course of the disease and the biologic mechanism that 
explain the clinical manifestation of CUP. In the early 
nineties, a large series with 657 consecutive patients, 
reported decreased survival in cases with men, more 
organ site, adenocarcinoma histology, metastasis to 
lung, bone and pleura [14]. Since then, the importance 
of biomarkers and their identification by IHC has been 
extensively researched. We validated previously reported 
clinicopathologic factors associated with worse prognosis 
such as adenocarcinoma histology, multiple metastases 
beyond lymph nodes, bone metastases and good risk 
group based on Culine’s prognostic model in this cohort. 
Several clinicopathologic factors related with adverse 
clinical outcome of CUPs were suggested including 
adenocarcinoma histology, poor performance status, 
multiple disseminated metastases, and elevated LDH, 
compatible with the results of this study, and they are 
summarized in Table 4. 
Unique findings in this cohort were the relation 
between expressions of biomarkers with the unfavorable 
clinical behaviors. CA19-9, CEA, and LDH elevation in 
the serum test and CK20 positivity in the tumor tissue 
were proven to be related with the shorter overall survival 
in univariate analysis. Especially, CK20 positivity was 
related to unfavorable overall survival in the multivariable 
analysis. Prognostic value of CK20 expression was 
validated in a subset of urothelial carcinomas and 
colorectal carcinomas [15-17]. This type of keratin, CK20, 
is a major cellular protein of mature enterocytes and goblet 
cells and specially expressed in the gastric and intestinal 
mucosa, suggesting that CUP with immunophenotype 
of enterocytes may have intrinsic aggressive biological 
behavior. 
The potential limitation of this study is that the 
patient survival was not separately analyzed in the 
context of therapy given to each patient. Ever since 
new, broad spectrum antineoplastic chemotherapeutic 
drugs were introduced around late 1990s, combination 
of taxane and a platinum agent or gemcitabine and a 
platinum agent have been most commonly used for the 
treatment of the CUPs, but growing evidence showed 
a site-specific therapy based on the identified primary 
tumor type result in improved patient survival [3, 18]. 
In this regard, recent research showing epigenetic profile 
guided tumor type specific therapy showing improved 
overall survival compared with that in patients who 
received empiric therapy is astonishing [10]. Tests based 
on mRNA or miRNA profile are commercially available 
and they appear to show reproducible results. Although 
the practical use of these approaches need to be studied 
in the light of cost and feasibility in the clinical practice, 
identification of subgroups that may be eligible for site 
specific therapy seems to be the most important question 
for the improvement of survival of patient with CUP. 
Table 3: Multivariable analysis of clinicopathologic factors related to survival
Variable HR 95% CI P
Culine’s prognostic model 
Poor risk group vs. good risk group 3.88 1.75-8.64 0.001
Histologic subtype
  Adenocarcinoma vs. other subtypes 1.51 0.76-2.97 0.24
Lymph node metastasis
Lymph node involement only vs. lymph node and distant organ metastasis 0.86 0.34-2.16 0.76
Bone metastsis 
  Present vs. absent 1.43 0.67-3.04 0.36
CA19-9 level
  Elevation vs. normal range 1.98 0.99-3.97 0.053
CK20 expression
  Positivity vs. negativity 3.31 1.42-7.70 0.005
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Prognostic model suggested by Culine was 
also validated in this cohort, suggesting that it would 
be appropriate to include this model in early clinical 
evaluation, considering its conciseness. Recently, Culine’s 
model was validated in 47 cancer of unknown primary 
origin in adolescents (CUP-AYA) [19]. Nevertheless, the 
clinical utility of this model need to be regarded in the 
context of the treatment as the current NCCN guideline 
suggests the site-specific treatment of CUP based on the 
information from the work-up as best as can be done. 
In conclusion, clinicopathologic factors related 
to the patient survival was analyzed, revealing CK20 
expression, adenocarcinoma histology, multiple 
metastases beyond lymph nodes, bone metastases, poor 
risk groups based on Culine’s models are factors related 
unfavorable outcome. Significance of these factors need 
to be considered in the context of eligibility of patients for 
the site-specific therapies. 
Figure 3: Kaplan-Meier survival estimates of CUP patients according to the clinicopathologic factors. Adenocarcinoma 
histology (P = 0.001), increased CA19-9 (P = 0.003), patients belonging to poor risk group in Culine’s model (P < 0.001), CK20 positivity 





This retrospective study was approved by the 
Institutional Review Board of Yonsei University Medical 
Center (approval number: 4-2015-0830). A total of 
106 consecutive cases from 106 patients of carcinoma 
of unknown primary origin were collected from the 
archives of pathology in Severance hospital during the 
period of 2000 to 2015. Patient records/information were 
anonymized and de-identified prior to clinicopathologic 
analyses. Vital status of the patient was confirmed by the 
national tumor registry and electronic medical record of 
the patients. 
The diagnostic inclusion criteria were adopted from 
the research of previously reported literatures [1, 20]. 
Clinically metastatic disseminated tumor
No definite increased specific serum tumor marker 
that can explain the lesion. 
No identified primary tumor site at presentation
Limited to epithelial and undifferentiated cancers
Stratification of the patients
To categorize the cases into ‘favorable’ and ‘non-
favorable’ groups, the following criteria were adopted 
from literatures [6]. 
Women with papillary adenocarcinoma of the 
peritoneal cavity
Table 4: Previous studies of prognostic factors in patients with CUP
Reference Number of Patients Adverse prognostic factorsUnivariated analysis Multivariable analysis
Kambhu [21] 57 Poor performance status Visceral metastases below the diaphragm
  Visceral metastases below the diaphragm  
Hainsworth 
[14] 220
Dominant tumor location outside 
retroperitoneum and peripheral lymph 
nodes
Dominant tumor location outside 
retroperitoneum and peripheral lymph 
nodes
Number of metastatic sites (>3) Number of metastatic sites (>3)
Elevated serum CEA Positive smoking history 
Elevated serum LDH Older age
  Positive smoking history  
Abbruzzese 
[22] 657 Male Male
Adenocarcinoma histology Adenocarcinoma histology
Number of metastatic sites Number of metastatic sites




  Brain metastases  
van der Gaast 
[23] 79 Poor performance status Poor performance status
Adenocarcinoma histology Elevated serum alkaline phosphatase
Bone mtastases
Liver metastases
Elevated serum alkaline phosphatase
  Serum AST  
Culine [13] 150 Performance status 2 or 3 Performance status 2 or 3
Liver metastases Elevated serum LDH
Elevated serum alkaline phosephatase
  Elevated serum LDH  
Raghav [19] 47 Number of metastatic sites >3 Number of metastatic sites >3
Elevated LDH Elevated LDH
Lung metastases Tissue of origin not tested
First line treatment
  Tissue of origin not tested  
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Women with adenocarcinoma involving the axillary 
lymph nodes
Poorly differentiated carcinoma with midline 
distribution
Poorly differentiated neuroendocrine carcinoma
Squamous-cell carcinoma involving cervical lymph 
nodes
Adenocarcinoma with a colon-cancer profile 
(CK20+, CK7-, CDX2+)
Men with blastic bone metastases and elevated 
prostate-specific antigen (adenocarcinoma)
Isolated inguinal adenopathy (squamous carcinoma)
Patients with one small, potentially resectable 
tumour
In addition, Culine’s prognostic model was applied 
and we classified the patients into group with good risk 
(ECOG performance status of 0 or 1 and normal LDH 
or no evidence of liver metastases if LDH is unknown) 
and poor risk (ECOG performance status of 2 or more 
or elevated LDH or presence of liver metastases if LDH 
unknown) [13].
Generation of tissue microarray
A representative area of H&E stained slides of each 
tumor and the corresponding spot was marked on the 
paraffin block. The area was punched out by the biopsy 
needle and a 3-mm tissue core was placed into a recipient 
block. More than 2 tissue cores were extracted to minimize 
extraction bias. Each tissue core was assigned.
Immunohistochemistry
We used a two-step strategy of IHC to assess CUPs 
according NCCN Guidelines [1]. First, we identified 
that tumors with occult primary tissue of origin were 
carcinomatous tumors using the following antibodies: 
broad spectrum cytokeratin (CK), S-100 protein, HMB45, 
and CD45. Next, staining for CK7 and CK20 is used 
to subtype carcinomas. We also used CDX-2 antibody 
because a recent report presented that patients with CUPs 
with lower gastrointestinal profile (CDX-2+, CK20+, 
CK7-) may have benefit from site-specific therapy [18]. 
Neuroendocrine differentiation was identified using IHCs 
for synaptophysin, chromogranin and CD56 in cases with 
histology with organoid arrangement such as solid/nesting, 
trabecular or gyriform pattern. Information of primary 
antibodies is presented as Supplementary Table 1.
Formalin-fixed, paraffin-embedded tissue sections 
from the tissue microarray were prepared for IHC. Briefly, 
5-μm-thick sections were obtained with a microtome, 
transferred into adhesive slides, and dried at 62°C for 30 
minutes. IHC was performed using an automated staining 
instrument (Ventana Discovery® XT, Ventana Medical 
System, AZ, USA) according to instruction. 
Statistics
Patients and tumor characteristics including age, 
gender, histologic type, treatment, immunohistochemistry 
against CK7, CK20 and CDX2, tumor markers (CEA, 
CA19-9, CA 12-5, CA 15-3, SCCAg, AFP, PIVKA-II), 
site of metastases were summarized using frequencies 
and percentages. Analysis of overall survival was 
performed using Kaplan-Meier’s method and log-rank 
tests. For adjustment of parameters affecting a patient’s 
survival, multivariable analysis was performed using Cox 
regression test. We checked the proportionality assumption 
of each variable using stphplot function of STATA 
software. Statistical significance was reached when P < 
0.05. Data were analyzed using TitleIBM Corp. Released 
2013. IBM SPSS Statistics for Windows, Version 22.0. 
Armonk, NY: IBM Corp.23 and Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP.
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